Best Practice of Overcoming Personalised Medicine Implementation Barriers co-funded ERA-PerMed Project 2018 Call *"Multidimensional stratification for treatment of acute kidney injury - Kidney Attack Project"* (Health Research Institute of Jiménez Díaz Foundation IIS-FJD)

> Alberto Ortiz, MD, PhD Chief of Nephrology and Hypertension Professor of Medicine

IIS-Fundacion Jimenez Diaz/Universidad Autonoma de Madrid





The issues

The ERA-PerMed Project

The barriers

Worldwide top projected causes of death by 2040

Leading causes 2016	Leading causes 2040	Mean % change number of YLLs
1 Ischaemic heart disease	1 Ischaemic heart disease	-3·6 (-43·1 to 40·9)
2 Stroke	2 Stroke	-10·7 (-40·1 to 31·9)
3 Lower respiratory infections	3 Lower respiratory infections	-24.8 (-47.9 to 3.4)
4 Diarrhoeal diseases	4 COPD	32.1 (-13.0 to 98.4)
5 Road injuries	5 Chronic kidney disease	100-3 (8-3 to 302-1)
6 Malaria	6 Alzheimer's disease	131-2 (90-9 to 196-6)
7 Neonatal preterm birth	7 Diabetes	76.7 (10.3 to 228.8)
8 HIV/AIDS	8 Road injuries	-18·3 (-31·7 to 8·5)
9 COPD	9 Lung cancer	20.7 (-9.0 to 60.5)
10 Neonatal encephalopathy	10 Diarrhoeal diseases	-39·7 (-76·5 to 47·0)
11 Tuberculosis	11 Self-harm	7·8 (-15·2 to 41·9)
12 Congenital defects	12 HIV/AIDS	-30·4 (-41·8 to -20·3)
13 Lung cancer	13 Liver cancer	69.6 (30.7 to 135.2)
14 Self-harm	14 Hypertensive heart disease	89·9 (6·3 to 358·7)
15 Diabetes	15 Colorectal cancer	59·1 (18·3 to 123·9)
16 Chronic kidney disease	16 Tuberculosis	-40-0 (-52-8 to -19-7)
17 Other neonatai	17 Congenital defects	-41·0 (-50·6 to -30·5)
18 Alzheimer's disease	18 Neonatal preterm birth	-57.0 (-66.4 to -48.9)


Foreman KJ et al. Lancet 2018; 392: 2052–90

YLL: years of life lost

What is AKI? Acute Kidney Injury	What is CKD?	
	Either of the following for >3 months)	
Currently missing	 Markers of kidney damage (one) Albuminuria (>30 mg/g creatinine) Abnormalities detected by histology Other 	
Serum creatinine increases ≥0.3 mg/dl in 48h	Or 2. Decreased GFR (<60 ml/min/1.73 m ²)	
or >50% in 7 days		

 Kidney Int supl 2012
 KDIGO Clinical Practice Guideline for Acute Kidney Injury


AKI: the traditional view



Epidemiology of Acute Kidney Injury

Jorge Cerdá,* Norbert Lameire,[†] Paul Eggers,[‡] Neesh Pannu,[§] Sigehiko Uchino,[∥] Haiyan Wang,[¶] Arvind Bagga,** and Adeera Levin^{††}

TIMF Clin J Am Soc Nephrol 3: 881-886, 2008



Epidemiology of Acute Kidney Injury

Jorge Cerdá,* Norbert Lameire,[†] Paul Eggers,[‡] Neesh Pannu,[§] Sigehiko Uchino,[∥] Haiyan Wang,[¶] Arvind Bagga,** and Adeera Levin^{††}



Where do the GFR and albuminuria thresholds come from?

• For all-cause and cardiovascular **death**


• For CKD progression

Death, the **ultimate outcome**

Risk

premature! • The issue is not if, but when

A CKD diagnosis



CKD is the risk factor associated with **highest** COVID-19 **mortality** after old age





Figure 1



Nephrol Dial Transplant (2018) 1–11 doi: 10.1093/ndt/gfx376

2018




Beatriz Fernandez-Fernandez^{1,2,3,a}, M. Concepcion Izquierdo^{1,2,3,5,a}, Lara Valiño-Rivas^{1,2,3}, Dimitra Nastou⁴, Ana B. Sanz^{1,2,3}, Alberto Ortiz^{1,3,b} and Maria D. Sanchez-Niño^{1,2,3,b}

Control

Albuminuria

ndt






Current AKI definition

• One size fits all

Serum creatinine increases **≥0.3** mg/dl in **48**h



Late diagnosis!




AKI: closing the stable door after the horse has bolted

There is **no treatment for AKI:**

Earlier diagnosis of AKI or of AKI risk will allow welldesigned RCT assessing treatment

Sanz et at. Nat Rev Nephrol (under review) Martin-Sanchez D et al. PNAS USA 2018 Martin-Sanchez D et al., JASN 2017




The issues

The ERA-PerMed Project

The barriers

Multidimensional stratification for treatment of acute kidney injury KIDNEY ATTACK Coordinator Alberto Ortiz, IIS-FJD UAM, Madrid, Spain



Aims

• Assess the performance of **combination of multiomics** traits and clinical observations for **early stage stratification** of **cardiac surgery**-related AKI. Recruitment **stopped March 2020**


• Select new compounds and drugs for AKI based on combination of existing database and literature data.

• Develop translational humanized readouts in animal models of AKI by integration of AKI-specific human and animal model omics signatures.


• Screen of novel AKI drugs with high translational value in preclinical AKI models based on humanized readouts.

RESEARCH

Open Access



Alexis Piedrafita^{1,2,3†}, Justyna Siwy^{4†}, Julie Klein^{2,3†}, Amal Akkari⁵, Ana Amaya-garrido², Alexandre Mebazaa⁶, Anna Belen Sanz⁷, Benjamin Breuil^{2,3}, Laura Montero Herrero⁷, Bertrand Marcheix^{3,8}, François Depret⁶, Lucie Fernandez², Elsa Tardif⁹, Vincent Minville^{3,9}, Melinda Alves², Jochen Metzger⁴, Kidney Attack Study Group, Julia Grossac⁹, Harald Mischak⁴, Alberto Ortiz⁷, Stéphane Gazut⁵, Joost P. Schanstra^{2,3*†}, Stanislas Faguer^{1,2,3*†}, Nicolas Mayeur⁹, Audrey Casemayou¹⁰ and François Labaste⁹



PLOS ONE

G OPEN ACCESS 💋 PEER-REVIEWED


CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis

Àngel Argilés 🕱, Justyna Siwy, Flore Duranton, Nathalie Gayrard, Mohammed Dakna, Ulrika Lundin, Lourdes Osaba,

Christian Delles, Georges Mourad, Klaus M. Weinberger, Harald Mischak 🕱 🖾

Published: May 14, 2013 • https://doi.org/10.1371/journal.pone.0062837

Capillary electrophoresis-mass spectrometry (CE-MS)








Fig. 1 Patient flowchart for the identification and validation of a predictive AKI urinary peptide signature. Three independent cohorts were used: a derivation CBP surgery cohort (n = 509), a validation CBP surgery cohort (n = 661)—both recruited in the University Hospital of Toulouse (France), but during different time periods—and an external ICU cohort (external ICU validation multicenter cohort [25], n = 2087). Sixty-three patients from the derivation and 181 from the validation CBP surgery cohorts were excluded because of missing urine samples or failure of the urinary peptidome analysis pipeline. Five hundred eighteen patients from the external ICU validation cohort were excluded because of missing urine samples, failure of the urinary peptidome analysis pipeline, or missing information with respect to the development or presence of AKI. *CBP surgery*, cardiac bypass surgery; *ICU*, intensive care unit



Heart surgery


Prediction of AKI



False positive rate




Prediction of AKI




Diagnosis	AUC [95%CI]	p-value
Cardiac Arrest (n = 140)	0.71 [0.62- 0.80]	0.050
Hemodynamic (n = 193)	0.81 [0.75- 0.88]	0.374
Septic (n = 378)	0.78 [0.74- 0.83]	0.862
Post-Operative (n = 146)	0.86 [0.80- 0.92]	0.024
Acute Respiratory Failure (n= 325)	0.72 [0.66- 0.79]	0.025
Neurological failure (n = 240)	0.74 [0.64- 0.84]	0.408
Others (n = 154)	0.74 [0.65- 0.74]	0.189

Interpretation: U peptidomics main advantage is early identification of kidney injury

Urinary peptides





Urine metabolomics



A Journal of The Pathological Society Understanding Disease


Original Article

Ferrostatin-1 modulates dysregulated kidney lipids in acute kidney injury

Lucía Martín-Saiz, Juan Guerrero-Mauvecin, Diego Martín-Sanchez, Olatz Fresnedo, Manuel J Gómez, Susana Carrasco, Pablo Cannata-Ortiz, Alberto Ortiz 🔀, José A Fernandez 🔀, Ana B Sanz 🔀

```
First published: 13 February 2022 | https://doi.org/10.1002/path.5882
```

Vitamin K, ferroptosis and AKI



The issues

The ERA-PerMed Project

The barriers

Clinical need: Yes

Industry partner can provide the product: Yes

Is the technology available and in clinical use: Yes

Does implementation result in improved outcomes: do not know yet

Is implementation cost-effective **do not know yet**

- Pragmatic clinical trial Barrier: funding
- **Decide** to initiate **therapy** early based on **u-peptidomics** results
- Assess impact on **outcomes Barrier: what drug**

Barrier: turn around time


Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Nete Tofte*, Morten Lindhardt*, Katarina Adamova, Stephan J L Bakker, Joachim Beige, Joline W J Beulens, Andreas L Birkenfeld, Gemma Currie, Christian Delles, Ingo Dimos, Lidmila Francová, Marie Frimodt-Møller, Peter Girman, Rüdiger Göke, Tereza Havrdova, Hiddo J L Heerspink, Adriaan Kooy, Gozewijn D Laverman, Harald Mischak, Gerjan Navis, Giel Nijpels, Marina Noutsou, Alberto Ortiz, Aneliya Parvanova, Frederik Persson, John R Petrie, Piero L Ruggenenti, Femke Rutters, Ivan Rychlík, Justyna Siwy, Goce Spasovski, Marijn Speeckaert, Matias Trillini, Petra Zürbig, Heiko von der Leyen, Peter Rossing, for the PRIORITY investigators†

Lancet Diabetes Endocrinol . 2020 Apr;8(EU funded

U proteomics **correctly identified** fast progressors

The intervention did not improve outcomes



The NEW ENGLAND JOURNAL of MEDICINE

George L. Bakris, M.D., Rajiv Agarwal, M.D., Stefan D. Anker, M.D., Ph.D., Bertram Pitt, M.D., Luis M. Ruilope, M.D., Peter Rossing, M.D., Peter Kolkhof, Ph.D., Christina Nowack, M.D., Patrick Schloemer, Ph.D., Amer Joseph, M.B., B.S., and Gerasimos Filippatos, M.D., for the FIDELIO-DKD Investigators*